IG2
Latest Information Update: 29 Jul 2021
At a glance
- Originator Alexion Pharmaceuticals
- Class
- Mechanism of Action T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 27 Jun 2001 Discontinued-Preclinical for Type-1 diabetes mellitus in USA (Unknown route)
- 15 Feb 1999 New profile